Physician profile
Sumitabh Singh
NPI 1114591328
$7,856.85
in general payments reported to CMS, 2019-2025
11 companies · $7,738 in 2025
The $7,738 reported for 2025 was more than what 98% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $118 · 2025: $7,738.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,768 · Food and Beverage: $3,765 · Education: $222.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,767.90 |
| Food and Beverage | $3,764.91 |
| Education | $222.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,754.92 | 2025 | Gallant, Ensite, Mitraclip |
| Biotronik INC. | $2,441.95 | 2025 | |
| Medtronic, INC. | $1,529.27 | 2025 | Corevalve Evolut R, Azure Xt Dr Mri Surescan |
| Bridgebio Pharma, INC. | $293.37 | 2025 | Attruby |
| Cardiva Medical, INC. | $198.95 | 2025 | Cardiva Vascade 6/7f Vcs, Cardiva Vascade 5f Vcs, Cardiva Vascade Mvp Vvcs 6-12f |
| Amgen INC. | $188.36 | 2024-2025 | Repatha, Repatha |
| Edwards Lifesciences Corporation | $158.86 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $76.34 | 2025 | Wainua |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.85 | 2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $46.63 | 2025 | Camzyos |
| Pfizer INC. | $14.75 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sumitabh Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.